Fragment Length of Circulating Tumor DNA.

Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, Gligorich KM, Rostomily RC, Bronner MP, Shendure J. · 2016

Read Fragment Length of Circulating Tumor DNA. by Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, Gligorich KM, Rostomily RC, Bronner MP, Shendure J. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4948782.txt.

Introduction

Hunter R. Underhill and nine co-authors show that tumor DNA floating in blood comes in shorter pieces than normal free DNA. Their study appeared in PLoS Genetics in 2016. Tumors shed DNA into the bloodstream, which raises the hope of cancer tests from a simple blood draw. The tumor share is tiny next to DNA from healthy cells, above all when cancer has not spread. The team compared fragment lengths in rats bearing human tumors and in people with cancer.

Human tumor DNA in rat blood peaked at 134 to 144 base pairs, against 167 for the rat's own free DNA. Human patients with melanoma and lung cancer showed the same shift versus healthy controls. In one melanoma patient, the mutant gene copy sat in shorter fragments than the normal copy. The authors argue that selecting short fragments can enrich tumor DNA and sharpen blood based cancer tests.

Catalog record

CREATORUnderhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, Gligorich KM, Rostomily RC, Bronner MP, Shendure J.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE85 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4948782

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Fragment Length of Circulating Tumor DNA By Hunter R Underhill, Jacob O Kitzman, Sabine Hellwig, Noah C Welker, Riza Daza, Daniel N Baker, Keith M Gligorich, Robert C Rostomily, Mary P Bronner, Jay Shendure, David J Kwiatkowski Published in: PLoS Genetics DOI: 10.1371/journal.pgen.1006162 ABSTRACT Abstract Malignant tumors shed DNA into the circulation. The transient half-life of circulating tumor DNA (ctDNA) may afford the opportunity to diagnose, monitor recurrence, and evaluate response to therapy solely through a non-invasive blood draw. However, detecting ctDNA against the normally occurring background of cell-free DNA derived from healthy cells has proven challenging, particularly in non-metastatic solid tumors. In this study, distinct differences in fragment length size between ctDNAs and normal cell-free DNA are defined. Human ctDNA in rat plasma derived from human glioblastoma multiforme stem-like cells in the rat brain and human hepatocellular carcinoma in the rat flank were found to have a shorter principal fragment length than the background rat cell-free DNA (134–144 bp vs. 167 bp, respectively). Subsequently, a similar shift in the fragment length of ctDNA in humans with melanoma and lung cancer was identified compared to healthy controls. Comparison of fragment lengths from cell-free DNA between a melanoma patient and healthy controls found that the BRAF V600E mutant allele occurred more commonly at a shorter fragment length than the fragment length of the wild-type allele (132–145 bp vs. 165 bp, respectively). Moreover, size-selecting for shorter cell-free DNA fragment lengths substantially increased the EGFR T790M mutant allele frequency in human lung cancer. These findings provide compelling evidence that experimental or bioinformatic isolation of a specific subset of fragment lengths from cell-free DNA may improve detection of ctDNA. INTRODUCTION Increased quantity of cell-free DNA in the circulation has been associated with malignant solid tumors [1]. Longitudinal studies have reported reductions in cell-free DNA quantity in response to therapy and elevations associated with recurrence suggesting quantification of cell-free DNA may be useful for monitoring disease status [2–4]. However, quantifying cell-free DNA as a marker of disease and its extent has been limited. The quantity of cell-free DNA has not correlated well with stage and histological subtype [5, 6]. In addition, large inter-subject variations of cell-free DNA quantification have been described leading to overlap between malignant disease, benign tumors, and healthy controls [7, 8]. Moreover, increased quantity of cell-free DNA is non-specific to cancer and has been associated with other conditions such as autoimmune disease and environmental exposures [9, 10]. Finally, except in patients with advanced metastatic disease, tumor-derived cell-free DNA (i.e., circulating tumor DNA, ctDNA) forms only a small minority of the cell-free DNA in circulation against a background of fragments mostly derived from normal cells. Therefore, the quantification of cell-free DNA alone is of little prognostic value. As an alternative, detecting specific variants or mutational hotspots in ctDNA may have important clinical implications in the shift towards personalized medicine for diagnosing and/or monitoring malignancies. In lung cancer, EGFR mutations in ctDNA have been associated with prognosis and utilized for determining therapy (e.g., activating mutations that confer sensitivity to tyrosine kinase inhibitors) [11]. However, molecular ctDNA studies in a variety tumor types have largely focused on advanced or metastatic disease in which ctDNA is more readily detectable compared to localized disease [12]. Bettegowda et al. reported a substantial reduction in detectability of ctDNA in localized disease compared to metastatic tumors for breast, colon, pancreas, and gastroesophageal cancers [13]. Moreover, ctDNA from glioblastoma multiforme (GBM), a primary brain tumor associated with neovascularization and disruption of the blood-brain barrier, was undetectable [13]. This latter finding supports the general perception that detection of ctDNA from non-metastatic solid tumors is particularly challenging since GBM does not metastasize beyond the central nervous system. Emerging approaches to improve detection of ctDNA include amplicon-based strategies in colorectal cancer [14] and integrated digital error suppression during deep sequencing in lung cancer [15]. While the latter methods seek to eliminate artifacts during sequencing to improve bioinformatic analytic sensitivity of mutant allele detection, the former techniques exploit apparent size differences between ctDNA and cell-free DNA. Specifically, previous amplicon-based studies have shown that ctDNA is highly fragmented and occurs most commonly at a size <100 bp, while normal cell-free DNA is proportionally more represented at a size >400 bp [16]. In this study, we initially sought to determine the feasibility of detecting ctDNA associated with GBM by utilizing a xenograft tumor model to exploit genomic species differences to separate ctDNA from the background host animal benign cell-free DNA. In so doing, we identified precise differences in fragment lengths between ctDNA and normal cell-free DNA, which were more narrow and more consistent than previously described [16, 17]. In addition, we found strong evidence of a 10 bp periodicity in ctDNA that was less prominent in normal cell-free DNA. These observations led us to explore if similar findings were present in tumors outside the brain and subsequently translated to cell-free DNA samples obtained from cancer patients. Collectively, the results described herein demonstrate that the fractional selection of cell-free DNA with a specific size range that is 20–50 bp shorter than the size of normal healthy cell-free DNA may substantially enrich for ctDNA in human cancer. RESULTS GBM Xenograft Model Established human GBM stem-like cell lines (GBM4 and GBM8) [18, 19] were implanted in the nude rat brain. Control animals underwent an identical surgical procedure and were inoculated with medium only. Quantitative magnetic resonance imaging techniques were implemented on a 3T whole-body clinical scanner (Philips Achieva) to phenotype the tumors. Fast bound-pool fraction imaging (FBFI), a method validated with histology to measure myelin density and identify tumor associated disruption of normal brain tissues [20], was used to produce bound-pool fraction maps (f maps) to detect and differentiate between bulky and infiltrative lesions. The variable flip angle method [21] was used to measure T1 relaxivity (R1 maps, where R1 = 1/T1) before and after administration of gadolinium (gadopentetate dimeglumine, Bayer HealthCare), an intravenous contrast agent that shortens T1 and identifies disruption of the blood-brain barrier (i.e., hyperintense signal on post-contrast R1 maps relative to pre-contrast R1 maps). Our initial experiments found that GBM4 yielded small, focal, non-enhancing lesions (Fig 1A and 1B, S1A and S1B Fig). In contrast, GBM8 produced heterogenous lesions that ranged from large, well-circumscribed tumors with strong contrast enhancement (i.e. disruption of the blood-brain barrier) to infiltrative lesions with absent or minimal contrast enhancement (Fig 1A and 1B, S1A and S1B Fig). [Figure: Periodicity and shorter fragment length of ctDNA derived from GBM8.In A, coronal f maps and pre- and post-contrast R1 maps with matched histology (B) and percent of human ctDNA detected in rat plasma (C, colored arrows identify results that correspond to images in A). GBM42 is a small tumor (A, white arrow) confirmed on histology (B, black box) with no evidence of a disrupted blood-brain barrier (i.e., post-contrast enhancement on R1 maps; A). In GBM81, a large tumor (white arrow on f map) is associated with disruption of the blood-brain barrier above the corpus callosum, but not below (asterisk on f map). GBM83 is an infiltrating tumor (white arrow) with no evidence of blood-brain barrier disruption, but possible invasion into the ventricle as identified on histology (B, black box). GBM84 is a large

Read the complete text